£810 / $1295 / €985
Online, PDF
While it is clear that drugmakers operating in Romania are far from happy with the latest revisions to the pharmaceutical claw-back tax, andthe tax remains unfairly punitive, all things considered, the August 2012 amendmentsarea small improvement, thoughdefinitelynot what producers would have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness of payments for reimbursed medicines, which has been a major difficulty for drug producers and distributors over the last four years, there are some upsides to this mechanism working effectively.The tax remains most punitive for generic drugmakers with lower-value medicines and could lead to these cheaper medicines exiting the market. The tax continues to weigh on BMI's assessment of Romania's Pharmaceutical and Healthcare Risk/Reward ratings.
Headline Expenditure Projections :
Pharmaceuticals: RON12.76bn (US$4.18bn) in 2011 to RON13.52bn (US$3.78bn) in 2012; +6.0% in local currency terms and -9.7% in US dollar terms. Local currency forecast slightly down from Q4 12 on account of macroeconomic factors; US dollar forecast further impacted by exchange rate factors.
Healthcare: RON30.17bn (US$9.90bn) in 2011 to RON32.07bn (US$9.86bn) in 2012; +6.3% in local currency terms and -9.5% in US dollar terms. Local currency forecast slightly down from Q4 12 on account of macroeconomic factors; US dollar forecast further impacted by exchange rate factors.
Medical devices: RON1.61bn (US$527mn) in 2011 to RON1.69bn (US$471mn) in 2012; +5.0% in local currency terms and -10.6% in US dollar terms. Local currency forecast slightly down from Q4 12 on account of macroeconomic factors; US dollar forecast further impacted by exchange rate factors.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.